{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:28:58Z","timestamp":1786649338074,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The aim of this study was to present the outcomes of the Vitreo-retinal Society of India (VRSI) Practice Pattern Survey 2020 in medical retina.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An online survey of members of VRSI was conducted in April 2020 regarding their practice-patterns on varied medical and surgical retina topics concerning imaging and management approach. The results were evaluated by two independent experts in this field and compared with the evidence and other practice patterns in the world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 107 VRSI members participated in the online survey. Responses were obtained on management of wide-ranging chorioretinal disorders such as Central Serous Chorioretinopathy (CSCR), Polypoidal Choroidal Vasculopathy (PCV), Neovascular age related macular degeneration (n-AMD), Retinal Vein Occlusions (RVO), and Diabetic Retinopathy (DR). Participants were also surveyed regarding their attitudes and perceptions about anti-VEGF practice patterns and role of imaging in their current practice. Each of the survey question responses were then compared to contemporary literature, including evidence-based guidelines, randomized controlled trials (RCTs), real-world evidence and analogous international surveys. Comprehensive analysis related to this has been put forward in the article.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This survey represents the contemporary practice patterns amongst vitreoretinal specialists in India. The survey results are vital for fellow practitioners to understand the \u2018standard of care\u2019 practice in medical retina. This will guide them to devise the best possible individualized treatment strategy for most favorable clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2573_20","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T10:42:08Z","timestamp":1622630528000},"page":"1430-1439","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Vitreoretinal Society of India practice pattern survey 2020: Medical retina"],"prefix":"10.4103","volume":"69","author":[{"given":"Jay U","family":"Sheth","sequence":"first","affiliation":[{"name":"Department of Vitreoretinal Services, Surya Eye Institute and Research Center, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingam","family":"Gopal","sequence":"additional","affiliation":[{"name":"Senior Consultant, Department of Ophthalmology, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gillies","sequence":"additional","affiliation":[{"name":"The University of Sydney, Faculty of Medicine, Save Sight Institute, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Khatri","sequence":"additional","affiliation":[{"name":"Director, Department of Vitreoretina, Eydox Eye Hospital and Rajan Eye Care Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch","family":"Kuppermann","sequence":"additional","affiliation":[{"name":"Gavin Herbert Eye Institute, University of California Irvine, Irvine, Calif., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupak","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Vitreo Retina, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobhit","family":"Chawla","sequence":"additional","affiliation":[{"name":"Medical Director, Prakash Netra Kendr, Lucknow, India"},{"name":"Vitreoretinal Society of India (VRSI), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Rajendran","sequence":"additional","affiliation":[{"name":"Vitreoretinal Society of India (VRSI), India"},{"name":"Retina-Vitreous Services, Aravind Eye Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Vitreoretinal Society of India (VRSI), India"},{"name":"Suven Clinical Research Center, LV Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"R1-20251004","first-page":"343","article-title":"Evidence-based medicine: Common misconceptions, barriers, and practical solutions","volume":"98","author":"Siwek","year":"2018","journal-title":"Am Fam Physician"},{"key":"R2-20251004","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jacr.2006.12.007","article-title":"Evidence-based medicine","volume":"4","author":"Collins","year":"2007","journal-title":"J Am Coll Radiol"},{"key":"R3-20251004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2017.02.003","article-title":"Why evidence-based medicine failed in patient care and medicine-based evidence will succeed","volume":"84","author":"Horwitz","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"R5-20251004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archopht.1974.03900060257001","article-title":"Experience with nontreatment of central serous choroidopathy","volume":"91","author":"Klein","year":"1974","journal-title":"Arch Ophthalmol"},{"key":"R6-20251004","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3928\/23258160-20170630-07","article-title":"Early focal laser photocoagulation in acute central serous chorioretinopathy: A prospective, randomized study","volume":"48","author":"Ambiya","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R7-20251004","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/IAE.0000000000001502","article-title":"Subfoveal choroidal thickness and vascular diameter in active and resolved central serous chorioretinopathy","volume":"38","author":"Chung","year":"2018","journal-title":"Retina"},{"key":"R8-20251004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10792-013-9774-y","article-title":"Choroidal thickness measurements during central serous chorioretinopathy treatment","volume":"34","author":"Brandl","year":"2014","journal-title":"Int Ophthalmol"},{"key":"R9-20251004","doi-asserted-by":"crossref","first-page":"8491712","DOI":"10.1155\/2020\/8491712","article-title":"Long-term effect of half-fluence photodynamic therapy on fundus autofluorescence in acute central serous chorioretinopathy","volume":"2020","author":"Stattin","year":"2020","journal-title":"J Ophthalmol"},{"key":"R10-20251004","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/jcm8091398","article-title":"Transfoveal micropulse laser treatment of central serous chorioretinopathy within six months of disease onset","volume":"8","author":"Gaw\u0119cki","year":"2019","journal-title":"J Clin Med"},{"key":"R11-20251004","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE trial","volume":"125","author":"Van Dijk","year":"2018","journal-title":"Ophthalmology"},{"key":"R12-20251004","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11096-017-0460-4","article-title":"Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: A meta-analysis","volume":"39","author":"Ji","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"R13-20251004","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/eye.2013.236","article-title":"Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: Meta-analysis and review","volume":"27","author":"Chung","year":"2013","journal-title":"Eye (Lond)"},{"key":"R14-20251004","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41433-019-0568-y","article-title":"Oral medications for central serous chorioretinopathy: A literature review","volume":"34","author":"Fusi-Rubiano","year":"2020","journal-title":"Eye (Lond)"},{"key":"R15-20251004","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R16-20251004","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: A randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R17-20251004","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/jamaophthalmol.2019.5628","article-title":"Cost-effectiveness of intravitreal ranibizumab with verteporfin photodynamic therapy compared with ranibizumab monotherapy for patients with polypoidal choroidal vasculopathy [published online ahead of print, 2020 Jan 9]","volume":"138","author":"Doble","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R18-20251004","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"key":"R19-20251004","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.survophthal.2017.05.006","article-title":"The application of optical coherence tomography angiography in retinal diseases","volume":"62","author":"Sambhav","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"R21-20251004","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/IAE.0b013e3182278b64","article-title":"Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy","volume":"32","author":"Wessel","year":"2012","journal-title":"Retina"},{"key":"R22-20251004","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/IAE.0000000000000843","article-title":"Retinal vein occlusions, from basics to the latest treatment","volume":"36","author":"Ho","year":"2016","journal-title":"Retina"},{"key":"R23-20251004","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.ophtha.2014.06.011","article-title":"Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: The SHORE study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"R24-20251004","first-page":"510","article-title":"Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion","volume":"31","author":"Unsal","year":"2015","journal-title":"Pak J Med Sci"},{"key":"R25-20251004","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/archopht.1986.01050130044017","article-title":"Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group","volume":"104","year":"1986","journal-title":"Arch Ophthalmic"},{"key":"R26-20251004","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1038\/s41598-019-42982-5","article-title":"Branch retinal vein occlusion: Treatment outcomes according to the retinal nonperfusion area, clinical subtype, and crossing pattern","volume":"9","author":"Iida-Miwa","year":"2019","journal-title":"Sci Rep"},{"key":"R28-20251004","article-title":"Baseline findings. Central Vein Occlusion Study Group","year":"1993","journal-title":"Online J Curr Clin Trials"},{"key":"R29-20251004","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.ophtha.2008.02.026","article-title":"Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases","volume":"115","author":"Wakabayashi","year":"2008","journal-title":"Ophthalmology"},{"key":"R30-20251004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0161-6420(95)31052-4","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema","volume":"102","author":"Klein","year":"1995","journal-title":"Ophthalmology"},{"key":"R31-20251004","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial [published correction appears in JAMA Ophthalmol 2019;137:467]","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R32-20251004","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ophtha.2017.12.008","article-title":"Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS study)","volume":"125","author":"Figueira","year":"2018","journal-title":"Ophthalmology"},{"key":"R33-20251004","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: A randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"key":"R34-20251004","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000488602","article-title":"Real-life clinical effectiveness of Razumab\u00ae (the World\u203as First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A subgroup analysis of the pooled retrospective RE-ENACT study","volume":"241","author":"Sharma","year":"2019","journal-title":"Ophthalmologica"},{"key":"R35-20251004","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"R36-20251004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis","volume":"134","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R37-20251004","first-page":"1255","article-title":"Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: The CHROME study","volume":"9","author":"Lam","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R38-20251004","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","volume":"103","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"R39-20251004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ajo.2015.12.025","article-title":"Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema","volume":"164","author":"Bressler","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R40-20251004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","article-title":"Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: A DRCR network phase 2 randomized clinical trial","volume":"136","author":"Maturi","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R41-20251004","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11892-019-1226-2","article-title":"Imaging and biomarkers in diabetic macular edema and diabetic retinopathy","volume":"19","author":"Kwan","year":"2019","journal-title":"Curr Diab Rep"},{"key":"R42-20251004","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"R43-20251004","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4103\/ijo.IJO_1602_19","article-title":"All India Ophthalmological Society members' survey: Practice pattern of intravitreal anti-vascular endothelial growth factor injection","volume":"68","author":"Sundar","year":"2020","journal-title":"Indian J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2573_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:52:34Z","timestamp":1786647154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2573_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2573_20","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"2020-08-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}